Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

The therapeutic arsenal for the management of AML has expanded significantly in recent
years. Before 2017, newly diagnosed AML was treated with either standard cytarabine-and …

The understanding of the molecular pathobiology of acute myeloid leukemia (AML) has
spurred the identification of therapeutic targets and the development of corresponding novel …

The treatment landscape of acute myeloid leukaemia (AML) is evolving rapidly. Venetoclax
in combination with intensive chemotherapy or doublets or triplets with targeted or immune …

Importance Acute myeloid leukemia (AML) is a clonal hematopoietic cancer that disrupts
normal hematopoiesis, ultimately leading to bone marrow failure and death. The annual …

The first 5 decades of research in acute myeloid leukemia (AML) were dominated by the
cytarabine plus anthracyclines backbone, with advances in strategies including allogeneic …

Synergetic inhibition of FMS-like tyrosine kinase 3 (FLT3) and histone deacetylase (HDAC)
by small molecule chimera presents a promising therapeutic approach for acute myeloid …

The advent of molecularly targeted therapeutics has transformed the management of
patients with acute myeloid leukemia (AML). Particularly for individuals unfit for intensive …

The availability of FLT3 inhibitors has improved outcomes in AML harboring such mutations,
currently also reflected in disease stratification and recommendations. Newer inhibitors are …

Introduction The prognosis of relapsed/refractory acute myeloid leukemia (r/rAML) is dismal,
and allogeneic hematopoietic stem cell transplant (allo-HSCT) is a potential cure …